Risperidone and Explosive Aggressive Autism

Many autistic patients with mental retardation have difficulties with explosivity and aggression. They often prove resistant to various pharmacotherapeutic interventions. In this study, 11 male outpatients (mean 18.3 years) were administered risperidone in an open-label fashion. The risperidone was started at 0.5 mg daily, and titrated upwards until maximum clinical benefit occurred. Serial clinical interviews were conducted, and Conners Parent-Teacher Questionnaires (short form) were completed by the caretakers. Substantial clinical improvement was noted almost immediately in each patient, with aggression, self-injury, explosivity, and poor sleep hygiene most improved. The modal dose for optimal response was 0.5 mg bid. Weight gain was a significant side effect (average velocity of 0.47 kg per week), while none of the patients experienced extrapyramidal side effects.

[1]  A. Labelle,et al.  Risperidone in the Treatment of Pervasive Developmental Disorder , 1994, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[2]  E. Haller,et al.  Risperidone and NMS? , 1995, Psychiatric services.

[3]  J. Bemporad,et al.  Brief report: Open trial effects of beta-blockers on speech and social behaviors in 8 autistic adults , 1987, Journal of autism and developmental disorders.

[4]  A Labelle,et al.  A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. , 1993, Journal of clinical psychopharmacology.

[5]  G. Realmuto,et al.  Clinical effect of buspirone in autistic children. , 1989, Journal of clinical psychopharmacology.

[6]  Fischer Je,et al.  Neurotransmitters and food intake. , 1993 .

[7]  E. Schopler,et al.  Classification of pervasive developmental disorders: Some concepts and practical considerations , 1992, Journal of autism and developmental disorders.

[8]  M. Ernst,et al.  Naltrexone in autistic children: behavioral symptoms and attentional learning. , 1993, Journal of the American Academy of Child and Adolescent Psychiatry.

[9]  B. Birmaher,et al.  Use of methylphenidate in the treatment of children with autistic disorder , 1995, Journal of autism and developmental disorders.

[10]  J. Rapoport,et al.  A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. , 1993, Archives of general psychiatry.

[11]  Najara Je,et al.  Risperidone and neuroleptic malignant syndrome: a case report. , 1995, The Journal of clinical psychiatry.

[12]  M. Drake.  Diagnostic and Statistical Manual of Mental Disorders (3rd ed. rev.) , 1988 .

[13]  M. Albus,et al.  D2‐dopamine receptor occupancy differs between patients with and without extrapyramidal side effects , 1994, Acta psychiatrica Scandinavica.

[14]  D. Giuliani,et al.  Effect on rat feeding behavior of two selective D2 dopamine agonists , 1994, Physiology & Behavior.

[15]  Virginia C. N. Wong.  Epilepsy in Children With Autistic Spectrum Disorder , 1993, Journal of child neurology.

[16]  B. Birmaher,et al.  CASE STUDY Methylphenidate Treatment of Hyperactive Autistic Children , 1988 .

[17]  J. Overall,et al.  Factors related to haloperidol response and dyskinesias in autistic children. , 1991, Psychopharmacology bulletin.

[18]  J. Addington,et al.  The use of fluoxetine and buspirone for treatment-refractory depersonalization disorder. , 1995 .

[19]  G. Chouinard,et al.  Clinical review of risperidone. , 1993, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[20]  Eric Schopler,et al.  Comparison of DSM-III-R and childhood autism rating scale diagnoses of autism , 1992, Journal of autism and developmental disorders.

[21]  K. Gadow.  Pediatric psychopharmacotherapy: a review of recent research. , 1992, Journal of child psychology and psychiatry, and allied disciplines.

[22]  J. Locascio,et al.  Repeated episodes of neuroleptic-related dyskinesias in autistic children. , 1991, Psychopharmacology bulletin.

[23]  M. Keshavan,et al.  Case study: risperidone in children and adolescents with schizophrenia. , 1995, Journal of the American Academy of Child and Adolescent Psychiatry.

[24]  F. Volkmar,et al.  Handbook of Autism and Pervasive Developmental Disorders , 1987 .

[25]  B. Leventhal,et al.  Clonidine Treatment of Hyperactive and Impulsive Children with Autistic Disorder , 1992, Journal of clinical psychopharmacology.

[26]  B. Leventhal,et al.  Fluoxetine treatment of children and adults with autistic disorder and mental retardation. , 1992, Journal of the American Academy of Child and Adolescent Psychiatry.

[27]  F. Volkmar,et al.  Seizure disorders in autism. , 1990, Journal of the American Academy of Child and Adolescent Psychiatry.